Questão 1118791

After drug registration, the benefit-risk assessment reports must be made by the regulatory agencies.

PV monitors the drug safety only through the assessment of adverse reactions due to overdose.

A drug’s lack of efficacy and misuse of heath products are relevant to PV.

The reporting of drug reactions to authorities must only be done by health care institutions.